NanoTemper Technologies GmbH, a Spin-Off of the Ludwig-Maximilians-University Munich, was founded in May 2008 in order to provide analytical services to pharmaceutical industry, biotechnology and research institues.
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate the delivery of foreign DNA into living cells.
nanoTools provides monoclonal and polyclonal antibody development services and products. Besides providing individually tailored custom solutions, the company develops, manufactures and markets phosphorylation and modification - state specific monoclonal antibodies and other innovative reagents for Signal Transduction and Alzheimer research, high throughput screening (HTS) and proteomics.
An early stage therapeutic drug company, NanoVector Inc. is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University. The NanoVector nanoparticle is a plant virus. Central to our technology, this virus, which has evolved over millions of years, has several inherent characteristics essential for a successful nanoparticle delivery system and superior to any designed and engineered by humans.
Nanoxis is a biotechnology company with extensive knowledge and experience in membrane protein research. Nanoxis has nanoscale technology solutions based on soft polymer and fluid-state liquid crystalline materials. The company is working on research and development of new nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. These technologies are applicable for production of biochips used in proteomics and genetics and as advanced components for nanofluidics, nanoelectronics and robotics.
Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.
Nicoya is a nanotechnology company developing novel sensor products. The company's flagship product is OpenSPR - a compact, sensitive, and affordable surface plasmon resonance instrument for molecular analysis.
Novavax is focused on creating novel, highly potent recombinant vaccines produced via cell culture. The company has developed three proprietary technology platforms: Virus-Like Particles, NovasomeŽ paucilamellar vesicles and Micellar Nanoparticles.
NST is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents (ApoSense - a small molecule 'Interfacial Nanoswitch') based on the identification and targeting of cells undergoing apoptosis.
OmegaGenesis, Inc. is a biotechnology company that discovers and produces nano-scale materials that work on the cellular and sub-cellular level to promote or inhibit angiogenesis, the growth of new blood vessels.
Oxford Nanopore Technologies Ltd is developing nanopore technology, a revolutionary method of molecular detection and analysis with potential applications in DNA sequencing, diagnostics, drug development and defence.
OZ Biosciences creates, develops and produces innovative tools based on drug delivery systems for the worldwide scientific community and pharmaceutical industry. OZ Biosciences focuses on technologies for the delivery of bioactive materials into living organisms.
Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, the company has created a powerful technology platform called single molecule, real-time, or SMRT, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform our understanding of biological systems by providing a window into these systems that has not previously been open for scientific study.
Parabon NanoLabs designs and develops a new class of therapeutics and other products made possible by proprietary technology for precisely directing the self-assembly of designer macromolecules that are functionalized with molecular subcomponents (e.g., enzymes, metals or pharmaceuticals).
Particle Sciences is an integrated provider of both standard and nanotechnology approaches to drug development and delivery. The company originally pioneered use of encapsulated ingredients and nanoparticles for sunscreens and personal care. In 1999 the company licensed a portion of its nanotechnology portfolio to BASF and focused its efforts on providing services to Life Sciences companies. Now, through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution designed to minimize the time and risk between discovery and the clinic.